HC Wainwright Begins Coverage on Molecular Partners (NASDAQ:MOLN)

Investment analysts at HC Wainwright began coverage on shares of Molecular Partners (NASDAQ:MOLN) in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm set a “buy” rating and a $13.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 213.56% from the company’s current price. HC Wainwright also issued estimates for Molecular Partners’ Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.43) EPS, Q3 2026 earnings at ($0.43) EPS, Q4 2026 earnings at ($0.44) EPS, FY2026 earnings at ($1.70) EPS, Q1 2027 earnings at ($0.45) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.39) EPS and FY2027 earnings at ($1.64) EPS.

A number of other equities analysts also recently commented on MOLN. JPMorgan Chase & Co. dropped their price objective on Molecular Partners from $4.00 to $3.75 and set a “neutral” rating on the stock in a report on Monday, December 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.58.

Molecular Partners Trading Up 3.7%

MOLN opened at $4.15 on Tuesday. The stock has a fifty day moving average price of $4.23 and a 200 day moving average price of $3.94. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.35. The stock has a market cap of $167.42 million, a price-to-earnings ratio of -2.16 and a beta of 1.07.

Molecular Partners (NASDAQ:MOLN) last posted its quarterly earnings results on Thursday, October 30th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.05. As a group, sell-side analysts forecast that Molecular Partners will post -1.93 earnings per share for the current fiscal year.

Key Molecular Partners News

Here are the key news stories impacting Molecular Partners this week:

• Positive Sentiment: HC Wainwright began coverage and assigned a Buy / Strong‑Buy rating with a $13.00 price target (about a 213% upside vs. the recent price), a clear catalyst drawing investor interest and buying pressure. Read More.
• Positive Sentiment: The analyst (R. Burns) published forward estimates that show improving losses: HC Wainwright models FY2026 EPS of -$1.70 and FY2027 EPS of -$1.64, which are less negative than the current consensus (~ -$1.93). That relative improvement underpins the bullish price target and supports upside expectations. Read More.
• Neutral Sentiment: HC Wainwright also released quarter‑by‑quarter EPS projections (Q1–Q4 2026 and Q1–Q4 2027: ~ -$0.39 to -$0.45), giving investors a detailed roadmap but no near‑term profitability signal; these are model assumptions rather than confirmed operational improvements. Read More.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.